ELV
Elevance Health, Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Buy
+36/100
Last price
400.09
▲ 5.58 (1.41%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
394.51
Day high
400.97
Day low
394.42
Volume
1.23M
Market cap
$86.77B
P/E (TTM)
17.71
52W range
274.84 – 436.24
Trailing performance
Returnvs SPY
1W
+1.87%
-0.1%
1M
-1.82%
-3.0%
3M
-3.84%
-8.4%
6M
+28.30%
+10.1%
YTD
+14.13%
-0.1%
1Y
+14.15%
-2.3%
3Y
-8.11%
-90.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ELV open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+11.46K
Net buying
Buy transactions
14
13.51K shares
Sell transactions
3
2.05K shares
Net transactions
+17
Buys less sells
Sell : buy shares
0.2 : 1
Mixed
Insider-held shares
412.05K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 2, 26 | KAYE MARK Chief Financial Officer |
STOCK | 2.63K | $0 | Direct |
| Jul 17, 26 | BOUDREAUX GAIL A KOZIARA Chief Executive Officer |
BUY | 2.73K | $1.00M | Direct |
| Jul 17, 26 | PERU RAMIRO G Director |
BUY | 1.00K | $366.05K | Direct |
| Jun 12, 26 | PENCZEK RONALD W Officer |
SELL | 369 | $148.77K | Direct |
| Jun 11, 26 | DIXON ROBERT L JR Director |
SELL | 151 | $60.67K | Direct |
| May 19, 26 | PENCZEK RONALD W Officer |
SELL | 1.53K | $617.19K | Direct |
| May 19, 26 | PENCZEK RONALD W Officer |
CONVERSION | 1.53K | $450.58K | Direct |
| May 13, 26 | JALLAL BAHIJA Director |
STOCK | 563 | $0 | Direct |
| May 13, 26 | NERI ANTONIO F Director |
STOCK | 563 | $0 | Direct |
| May 13, 26 | DEVORE SUSAN D Director |
STOCK | 563 | $0 | Direct |
| May 13, 26 | STRABLE-SOETHOUT DEANNA D Director |
STOCK | 563 | $0 | Direct |
| May 13, 26 | SCHNEIDER RYAN M. Director |
STOCK | 563 | $0 | Direct |
| May 13, 26 | COLLIS STEVEN HOWARD Director |
STOCK | 563 | $0 | Direct |
| May 13, 26 | SCHULMAN AMY W. Director |
STOCK | 563 | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BOUDREAUX GAIL A KOZIARA |
Chief Executive Officer | 172.04K | Purchase |
BOUDREAUX GAIL KOZIARA |
Chief Executive Officer | 169.31K | Stock Award(Grant) |
DIXON ROBERT L JR |
Director | 10.73K | Sale |
HAY LEWIS III |
Director | 12.07K | Stock Award(Grant) |
HAYTAIAN PETER D |
Officer | 27.22K | Stock Award(Grant) |
KAYE MARK |
Chief Financial Officer | 30.50K | Stock Award(Grant) |
KENDRICK CHARLES MORGAN JR |
Officer | 11.79K | Sale |
LAVU RATNAKAR |
Chief Technology Officer | 16.15K | Stock Award(Grant) |
NORWOOD FELICIA F. |
Officer | 38.84K | Stock Award(Grant) |
PERU RAMIRO G |
Director | 10.91K | Purchase |
Fundamentals
Market cap$86.77B
Enterprise value$80.44B
Revenue (TTM)$201.11B
Gross profit$52.27B
EBITDA$8.32B
Net income$4.96B
EPS (TTM)$22.59
Free cash flow$4.31B
Total cash$37.51B
Total debt$31.04B
Book value / share$206.99
Shares outstanding216.87M
Float216.38M
Short % of float2.75%
Dividend yield1.72%
Beta (5Y)0.71
Valuation & profitability ratios
Trailing P/E17.71
Forward P/E13.54
PEG ratio1.29
Price / sales—
Price / book1.93
EV / revenue0.40
EV / EBITDA9.66
Gross margin25.99%
Operating margin4.56%
Profit margin2.47%
Return on equity11.13%
Return on assets3.83%
Debt / equity68.95
Current ratio1.52
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $199.13B | $176.81B | $171.34B | $156.59B | — | +12.6% |
| Operating revenue | $199.13B | $176.81B | $171.34B | $156.59B | — | +12.6% |
| Selling, general & admin | — | — | — | $17.69B | $15.91B | — |
| Net interest income | -$1.40B | -$1.19B | -$1.03B | -$851.00M | — | -18.3% |
| Pre-tax income | $6.71B | $7.90B | $7.71B | $7.60B | — | -15.1% |
| Tax provision | $1.05B | $1.93B | $1.72B | $1.71B | — | -45.7% |
| Net income | $5.66B | $5.98B | $5.99B | $5.89B | — | -5.3% |
| Net income to common | $5.66B | $5.98B | $5.99B | $5.89B | — | -5.3% |
| Basic EPS | 25.65 | 26.29 | 25.69 | 25.32 | — | -2.4% |
| Diluted EPS | 25.21 | 25.68 | 25.22 | 24.81 | — | -1.8% |
| EBIT | $8.11B | $9.09B | $8.74B | $8.45B | — | -10.7% |
| Basic shares | 220.72M | 227.48M | 233.07M | 237.96M | — | -3.0% |
| Diluted shares | 224.60M | 232.90M | 237.40M | 242.80M | — | -3.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $9.49B | $8.29B | $6.53B | $7.39B | +14.5% |
| Cash & short-term investments | $35.38B | $33.49B | $36.14B | $33.34B | +5.6% |
| Accounts receivable | $10.07B | $8.01B | $7.90B | $7.08B | +25.7% |
| Property, plant & equipment | $4.68B | $4.65B | $4.36B | $4.32B | +0.6% |
| Goodwill & intangibles | $39.54B | $40.37B | $35.59B | $34.70B | -2.0% |
| Total assets | $121.49B | $116.89B | $108.93B | $102.75B | +3.9% |
| Long-term debt | $30.80B | $29.22B | $23.25B | $22.35B | +5.4% |
| Total debt | $32.05B | $31.23B | $25.12B | $24.11B | +2.6% |
| Total liabilities | $77.47B | $75.46B | $69.52B | $66.42B | +2.7% |
| Retained earnings | $35.39B | $33.55B | $31.75B | $29.65B | +5.5% |
| Shareholder equity | $43.88B | $41.31B | $39.31B | $36.24B | +6.2% |
| Net tangible assets | $4.34B | $944.00M | $3.72B | $1.54B | +359.5% |
| Shares issued | 220.72M | 227.48M | 233.07M | 237.96M | -3.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $5.66B | $5.97B | $5.99B | $5.89B | -5.2% |
| Depreciation & amortisation | $1.55B | $1.39B | $1.75B | $1.68B | +11.0% |
| Stock-based compensation | $276.00M | $191.00M | $289.00M | $264.00M | +44.5% |
| Change in working capital | -$3.28B | -$1.72B | -$535.00M | $423.00M | -90.6% |
| Operating cash flow | $4.29B | $5.81B | $8.06B | $8.40B | -26.1% |
| Capital expenditure | -$1.12B | -$1.26B | -$1.30B | -$1.15B | +11.1% |
| Investing cash flow | -$1.34B | -$5.17B | -$5.57B | -$4.56B | +74.0% |
| Share buybacks | -$2.60B | -$2.90B | -$2.68B | -$2.32B | +10.2% |
| Dividends paid | -$1.53B | -$1.51B | -$1.40B | -$1.23B | -1.4% |
| Financing cash flow | -$1.74B | $1.19B | -$3.35B | -$1.32B | -245.7% |
| Free cash flow | $3.17B | $4.55B | $6.76B | $7.25B | -30.3% |
| End cash position | $9.49B | $8.29B | $6.53B | $7.39B | +14.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $50.47B | $50.18B | $49.75B | $50.71B | $49.78B | +0.6% |
| Operating revenue | $50.47B | $50.18B | $49.75B | $50.71B | $49.78B | +0.6% |
| Net interest income | -$364.00M | -$357.00M | -$366.00M | -$351.00M | -$341.00M | -2.0% |
| Pre-tax income | $1.94B | $2.30B | $215.00M | $1.41B | $2.29B | -15.9% |
| Tax provision | $483.00M | $544.00M | -$331.00M | $219.00M | $548.00M | -11.2% |
| Net income | $1.46B | $1.76B | $547.00M | $1.19B | $1.74B | -17.1% |
| Net income to common | $1.46B | $1.76B | $547.00M | $1.19B | $1.74B | -17.1% |
| Basic EPS | 6.75 | 8.12 | 2.48 | 5.35 | 7.75 | -16.9% |
| Diluted EPS | 6.71 | 8.00 | 2.47 | 5.32 | 7.72 | -16.1% |
| EBIT | $2.30B | $2.66B | $581.00M | $1.76B | $2.63B | -13.5% |
| Basic shares | 216.84M | 217.37M | 220.72M | 222.04M | 224.84M | -0.2% |
| Diluted shares | 217.90M | 220.50M | 221.80M | 223.70M | 225.80M | -1.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $10.23B | $9.66B | $9.49B | $8.71B | $8.56B | +6.0% |
| Cash & short-term investments | $35.95B | $35.56B | $35.38B | $35.00B | $33.86B | +1.1% |
| Accounts receivable | $10.99B | $11.53B | $10.07B | $9.54B | $10.46B | -4.6% |
| Property, plant & equipment | $4.64B | $4.66B | $4.68B | $4.66B | $4.64B | -0.3% |
| Goodwill & intangibles | $39.32B | $39.43B | $39.54B | $39.78B | $39.86B | -0.3% |
| Total assets | $126.44B | $125.83B | $121.49B | $122.75B | $121.94B | +0.5% |
| Current debt | $375.00M | $1.07B | $1.25B | $929.00M | $2.01B | -65.1% |
| Long-term debt | $30.67B | $30.77B | $30.80B | $31.17B | $28.18B | -0.3% |
| Total debt | $31.04B | $31.84B | $32.05B | $32.10B | $30.19B | -2.5% |
| Total liabilities | $81.42B | $81.78B | $77.47B | $78.67B | $78.09B | -0.5% |
| Retained earnings | $36.67B | $35.80B | $35.39B | $35.59B | $35.55B | +2.5% |
| Shareholder equity | $44.88B | $43.90B | $43.88B | $43.95B | $43.72B | +2.2% |
| Net tangible assets | $5.56B | $4.47B | $4.34B | $4.17B | $3.86B | +24.4% |
| Shares issued | 216.84M | 217.37M | 220.72M | 222.04M | 224.84M | -0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $1.45B | $1.76B | $546.00M | $1.19B | $1.74B | -17.4% |
| Depreciation & amortisation | $366.00M | $354.00M | $406.00M | $387.00M | $380.00M | +3.4% |
| Stock-based compensation | $75.00M | $55.00M | $30.00M | $84.00M | $81.00M | +36.4% |
| Change in working capital | $40.00M | $2.66B | -$524.00M | -$750.00M | -$218.00M | -98.5% |
| Operating cash flow | $1.91B | $4.33B | $84.00M | $1.14B | $2.05B | -55.8% |
| Capital expenditure | -$287.00M | -$235.00M | -$293.00M | -$360.00M | -$267.00M | -22.1% |
| Investing cash flow | $159.00M | -$1.64B | $464.00M | -$1.22B | -$687.00M | +109.7% |
| Share buybacks | -$234.00M | -$1.12B | -$471.00M | -$876.00M | -$378.00M | +79.2% |
| Dividends paid | -$373.00M | -$376.00M | -$377.00M | -$381.00M | -$385.00M | +0.8% |
| Financing cash flow | -$1.49B | -$2.52B | $236.00M | $243.00M | -$308.00M | +40.6% |
| Free cash flow | $1.63B | $4.10B | -$209.00M | $775.00M | $1.79B | -60.3% |
| End cash position | $10.23B | $9.66B | $9.49B | $8.71B | $8.56B | +6.0% |
Options analytics
Put / call volume
2.05
Put-heavy session
Put / call open interest
0.07
Positioning, not flow
Max pain
270.00
-32.5% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
224
Contracts, this expiry
Put volume
459
Contracts, this expiry
Heaviest call OI
430.00
233 contracts
Heaviest put OI
220.00
5 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 6.21 | 7.45 | +20.0% |
| Mar 2026 | 10.81 | 12.58 | +16.4% |
| Dec 2025 | 3.09 | 3.33 | +7.6% |
| Sep 2025 | 4.94 | 6.03 | +22.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 4.68 | 19 | $49.12B | -1.9% |
| Next quarter | 2.43 | 19 | $48.12B | -2.4% |
| Current year | 27.23 | 22 | $196.24B | -0.7% |
| Next year | 29.59 | 22 | $200.39B | +2.1% |
Analyst targets & ownership
Mean target$451.48
High target$492.00
Low target$393.00
Implied upside12.84%
Analyst count21
ConsensusBUY
Strong buy / Buy3 / 12
Hold7
Sell / Strong sell0 / 0
Held by insiders0.19%
Held by institutions94.13%
Institutions holding2.16K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
393.17
+1.76% from price
SMA 20
402.76
-0.66% from price
SMA 50
397.99
+0.53% from price
SMA 100
398.02
+0.52% from price
SMA 200
366.28
+9.23% from price
EMA 12
395.91
+1.06% from price
EMA 26
398.87
+0.31% from price
EMA 50
398.08
+0.50% from price
RSI (14)
50.9
Neutral
MACD (12,26,9)
-2.96
Hist -1.37
ATR (14)
8.83
2.21% of price
Realised vol 30D
24.2%
Annualised
Bollinger upper
426.12
20, 2σ
Bollinger lower
379.40
20, 2σ
50 / 200 cross
Golden
397.99 vs 366.28
Trend bias
Above 200
+9.23%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.34
Less volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
24.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-26.5%
Peak to trough
Max drawdown 5Y
-51.2%
Peak to trough
ATR 14
8.83
2.21% of price
Beta (reported)
0.71
5Y monthly, from filing
Short interest
Shares short
5.34M
Prior 5.41M
Change vs prior
-1.3%
Shorts covering
% of float
2.75%
Normal
% of shares out
2.46%
Against total outstanding
Days to cover
5.1
Crowded exit
Float
216.38M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 17, 26 | Bernstein | MAINTAINED | Outperform | Outperform |
| Jul 17, 26 | Leerink Partners | MAINTAINED | Market Perform | Market Perform |
| Jul 16, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Jul 16, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Jul 16, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jul 16, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jul 16, 26 | Baird | MAINTAINED | Neutral | Neutral |
| Jul 14, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Jul 14, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Jul 13, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Jul 9, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Jul 7, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate$6.88 / yr
Forward yield1.72%
5-year avg yield1.30%
Payout ratio30.37%
Ex-dividend dateSep 10, 2026
Next pay dateSep 25, 2026
Last split2:1
Split dateJun 1, 2005
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-10
Corporate Changes & Voting Matters
8-K · 2026-07-15
Annual report of employee stock purchase
11-K · 2026-06-17
Corporate Changes & Voting Matters
8-K · 2026-06-10
Corporate Changes & Voting Matters
8-K · 2026-05-13
Corporate Changes & Voting Matters
8-K · 2026-04-22
Proxy Statements
DEFA14A · 2026-03-27
Corporate Changes & Voting Matters
8-K · 2026-03-10
Headlines
UnitedHealth Q3 Coming Up: Two Questions Investors Can't Ignore
Zacks · 18h ago
Barclays Adjusts Elevance Health Price Target to $469 From $457, Maintains Overweight Rating
MT Newswires · 23h ago
ELV or DHR: Which Is the Better Value Stock Right Now?
Zacks · 2d ago
Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2026 Results on October 21, 2026
Business Wire · 2d ago
Evercore ISI Adjusts Elevance Health Price Target to $430 From $440, Maintains In Line Rating
MT Newswires · 2d ago
Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?
Zacks · 5d ago
How Much Downside Is Left In CVS Health Stock?
Trefis · 5d ago
Elevance Health (ELV): Conviction Pays Off as Underwriting Disciplines Stabilize Margins
Insider Monkey · 6d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.